Overview

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.

Phase:

Phase 3

Details

Lead Sponsor:

Chiesi Farmaceutici S.p.A.

Treatments:

Beclomethasone
Bromides
Formoterol Fumarate
Glycopyrrolate